

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/852,966	05/10/2001	Rima Kaddurah-Daouk	AVZ-020CN	5588
959	7590 08/28/2002			
LAHIVE & COCKFIELD			EXAMINER	
28 STATE STREET BOSTON, MA 02109		•	KIM, VICKIE Y	
			ART UNIT	PAPER NUMBER
			1614	~
			DATE MAILED: 08/28/2002	3

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
· .		
Office Action Symmony	09/852,966	KADDURAH-DAOUK, RIMA
Office Action Summary	Examiner	Art Unit
Th MAILING DATE of this communication app	Vickie Kim	1614
The MAILING DATE of this communication app Period for Reply	ars on the cover sheet with th	Correspondence address so
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply b within the statutory minimum of thirty (30) will apply and will expire SIX (6) MONTHS f cause the application to become ABANDO	e timely filed days will be considered timely. rom the mailing date of this communication. NED (35 U.S.C. § 133).
1) Responsive to communication(s) filed on	·	
2a) This action is FINAL . 2b) Th	is action is non-final.	
3) Since this application is in condition for alloward closed in accordance with the practice under	ince except for formal matters Ex parte Quayle, 1935 C.D. 1	, prosecution as to the ments is 1, 453 O.G. 213.
Disposition of Claims		
4) Claim(s) 1-67 is/are pending in the application		
4a) Of the above claim(s) is/are withdray	wit from consideration.	
5) Claim(s) is/are allowed.		•
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.	ologion requirement	
8) Claim(s) <u>1-67</u> are subject to restriction and/or 6 Application Papers	election requirement.	
9) The specification is objected to by the Examine	r.	
10) The drawing(s) filed on is/are: a) accept		Examiner.
Applicant may not request that any objection to the		
11) The proposed drawing correction filed on		
If approved, corrected drawings are required in re		
12)☐ The oath or declaration is objected to by the Ex	aminer.	
Priority under 35 U.S.C. §§ 119 and 120		
13) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. § 11	9(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:	•	
1. Certified copies of the priority document	s have been received.	
2. Certified copies of the priority document	s have been received in Appli	cation No
 3. Copies of the certified copies of the prio application from the International Bu * See the attached detailed Office action for a list 	reau (PCT Rule 17.2(a)).	
14) Acknowledgment is made of a claim for domesti		
a) The translation of the foreign language pro	ovisional application has been	received.
Attachment(s)		· ····
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Inform	mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)

Art Unit: 1614

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-36, drawn to a method of treating a subject for skin disorder comprising administering to said subject an effective amount of creatine compounds.
 - II. Claims 37-67, drawn to a composition comprising an effective amount of creatine compound(s).
- 2. Inventions I and II are related as process of use and product. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the products(compositions) as claimed are used in a plurality of patentably distinct uses, as evidenced by numerous US patented literatures. And the process of use(i.e. treating skin disorders such as wrinkles, ageing, etc) are achieved by materially different products as evidenced by numerous patented or non-patented literatures.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and the search required for each group is not same, wherein a reference which anticipates the invention of Group I would not render the invention of Group II obvious, absent ancillary

Art Unit: 1614

art, restriction for examination purposes as indicated is proper. Even if there were unity of classification, the search of entire groups and/or genus in the non-patent literature(especially, non-patent literature) and database search (a significant part of a thorough examination) would be burdensome, it is undue burden for examiner for the accurate and proper examination, restriction for examination purposes as indicated is proper.

3. According to the election of the invention (group I or II), applicant is further required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Election of species

- 4. Claim 1 is generic to a plurality of disclosed patentably distinct species comprising a skin disorder as recited in the claims 6-11 (e.g free radicals, aging, sun radiation). Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.
- 5. Claims 12 is generic to a plurality of disclosed patentably distinct species comprising a creatine compound of the formula and the preferred species are recited in the claims 16-25. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Claims 26 and 35 are generic to a plurality of disclosed patentably distinct species comprising a creatine compound that is further combined with a second active agent(i.e a skin preserving agent or sunscreen(or sunblock)). Depending upon the election of species, if the skin preserving agent is elected, it is subject to further election

Art Unit: 1614

requirement where the species of the said agent has recited in the claims 28-32 the preferred species are recited in the claims 16-25. For example, claim 28 and 30 are patentably distinct, each from the other, as they have acquired a separate status in the art and/or require independent searches. It is noted that a reference to one combination of drugs would not be a reference to another combination of drugs under U.S. C. 103. Further, the claims read on a multitue of enhanced combinations of drugs which would require many field of searches that would be an undue burden on the examiner. Therefore, restriction for examination purposes is proper. MPEP 803.02.

- 6. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
- 7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie. Kim whose telephone number is 703-305-1675. The examiner can normally be reached on Tuesday-Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne. Seidel can be reached on 703-308-4725. The fax phone numbers for the organization where this application or proceeding is assigned are 703-746-3165 for regular communications and 703-746-3165 for After Final communications. Any inquiry of a general nature or

Art Unit: 1614

relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Vickie Kim,

Patent examiner August 26, 2002

Art unit 1614